Clinical trial · Observational
Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment
NCT03624751CI-TRIAL-00110129active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The prevalence of thyroid cancer has increased in recent decades. Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan. This is a prospective, observational study, aiming to observe the difference of metabolic profiles between patients choose Thyrogen® injection and Eltroxin® withdrawal.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radioiodine | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Zung's Self-reported depression scale
- timeFrame
- 1 month
- description
- Depression symtpoms
Secondary outcomes (7)
- measure
- Brain-derived neurotrophic factor
- timeFrame
- 1 month
- description
- BDNF
- measure
- orexin
- timeFrame
- 1 month
- description
- An associated factor for depression
- measure
- Body composition
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with diagnosis of thyroid cancer。 2. Patients who need radioiodine therapy or scan。 Exclusion Criteria: 1. Patients cannot cooperate with blood test.。 2. Patients cannot cooperate with radioiodine therapy。
References
Publications (0)
Data not yet available
No reference posted for this study.